Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Black cohosh

This article was originally published in The Tan Sheet

Executive Summary

Botanical comparable to placebo at reducing number, intensity of hot flashes among breast cancer patients, researchers report in May 15 Journal of Clinical Oncology. Only symptom improved by black cohosh (GlaxoSmithKline's Remifemin) was sweating, Judith Jacobson, Columbia University, et al., state. Randomized, double-blind, placebo-controlled trial involved 85 women over age 18 who had been treated for breast cancer at Columbia-Presbyterian Medical Center. Subjects took one tablet twice daily and completed four-day hot flash diaries at baseline and after 30 and 60 days; a subset of participants had follicle-stimulating hormone and luteinizing hormone measured

You may also be interested in...



CAM Use In Women, Minorities Surveyed By Columbia University

Results of a nationwide survey by Columbia University on women's use of complementary and alternative medicine, with a focus on minorities, are due for release this fall.

CAM Use In Women, Minorities Surveyed By Columbia University

Results of a nationwide survey by Columbia University on women's use of complementary and alternative medicine, with a focus on minorities, are due for release this fall.

CAM Use In Women, Minorities Surveyed By Columbia University

Results of a nationwide survey by Columbia University on women's use of complementary and alternative medicine, with a focus on minorities, are due for release this fall.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel